- Home
- EDSA vs RNAZ Comparison
EDSA vs RNAZ Comparison
Compare EDSA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- RNAZ
- Stock Information
- Founded
- EDSA 2015
- RNAZ 2016
- Country
- EDSA Canada
- RNAZ United States
- Employees
- EDSA N/A
- RNAZ N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- RNAZ Health Care
- Exchange
- EDSA Nasdaq
- RNAZ Nasdaq
- Market Cap
- EDSA 6.2M
- RNAZ 7.2M
- IPO Year
- EDSA N/A
- RNAZ 2021
- Fundamental
- Price
- EDSA $2.43
- RNAZ $8.08
- Analyst Decision
- EDSA Strong Buy
- RNAZ Strong Buy
- Analyst Count
- EDSA 1
- RNAZ 1
- Target Price
- EDSA $21.00
- RNAZ $20.00
- AVG Volume (30 Days)
- EDSA 5.9M
- RNAZ 4.3M
- Earning Date
- EDSA 02-14-2025
- RNAZ 03-31-2025
- Dividend Yield
- EDSA N/A
- RNAZ N/A
- EPS Growth
- EDSA N/A
- RNAZ N/A
- EPS
- EDSA N/A
- RNAZ N/A
- Revenue
- EDSA N/A
- RNAZ N/A
- Revenue This Year
- EDSA N/A
- RNAZ N/A
- Revenue Next Year
- EDSA N/A
- RNAZ N/A
- P/E Ratio
- EDSA N/A
- RNAZ N/A
- Revenue Growth
- EDSA N/A
- RNAZ N/A
- 52 Week Low
- EDSA $1.55
- RNAZ $2.66
- 52 Week High
- EDSA $5.59
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- EDSA 56.54
- RNAZ 48.31
- Support Level
- EDSA $2.30
- RNAZ $10.02
- Resistance Level
- EDSA $4.49
- RNAZ $11.30
- Average True Range (ATR)
- EDSA 0.30
- RNAZ 1.97
- MACD
- EDSA 0.05
- RNAZ -0.18
- Stochastic Oscillator
- EDSA 22.56
- RNAZ 26.75
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.